Clinical Trial Update: Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of VAY736 in patients with primary Sjogren's syndrome has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• VAY736

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Sjogren Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2024-10-29